TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03794492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil 500mg Tab. or 250mg Cap.
Description: - Orally, up to 1g BID(total 2g daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: - Orally, check the blood ceocentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3-8ng/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone/prednisolone
Description: - Methyprednisolone 500mg / Prednisolone 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: - IV, 20mg(before Kidney transplat) / 20mg(Day 4 of kidney transplant)
Study: NCT02754232

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemedical training
Description: Intervention will involve resistance training and anaerobic training
Study: NCT01341015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Single interventional group - patients agree to an ultrasound of potential ankle fracture, to be compared to standard of care xray.
Study: NCT04613739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: insurance navigation
Description: Intervention subjects will be offered access to AAFA's chat bot and navigation services. The chat bot is an artificial intelligence-enabled interactive online tool that can answer clinical and insurance-related questions and provide information on coverage options and how to find lower-cost alternatives for asthma care. Intervention participants will be given a link to access the chat bot. They will also be provided with information about AAFA's insurance navigation program, how it can help with finding coverage and managing asthma costs, and how to access it within AAFA's asthma community platform. Subjects can access AAFA's community platform and join the private group where they can ask questions and share resources, with moderation by AAFA staff. They will be able to send private messages to an AAFA navigator who can provide support about insurance issues, access to asthma care, and assistance with asthma costs. The navigator will offer telephonic follow-up as needed.
Study: NCT01687634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-home Mentor Mother visits
Description: Pregnant women will receive twice-monthly in-home (or telephone) visits from a Mentor Mother who will provide information about pregnancy, breastfeeding, nutrition, and infant care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Information Mailings
Description: Pregnant women will receive twice-monthly mailings that will provide information about pregnancy, breastfeeding, nutrition, and infant care.
Study: NCT00789620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: 1.5 mg/kg as Bolus intraoperative: 2 mg/kg/h postoperative: 1.3mg/kg/h during 24h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Bolus 0.15 ml/kg NaCl 0.9% NaCl 0.2 ml/kg/h Perfusor NaCl 0.9% 0.13 ml/kg/h Perfusor
Study: NCT00608751

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Study: NCT01718392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Study: NCT00209391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadodiamide Injection
Study: NCT05662748

Intervention type: DEVICE
Intervention: Transfemoral aortic valve replacement
Description: aortic valve replacement

Intervention type: DEVICE
Intervention: Transfemoral aortic valve replacement
Description: aortic valve replacement
Study: NCT01653145

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet A
Description: Dietary

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet A
Description: Dietary

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet A
Description: Dietary

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet B
Description: Dietary

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet B
Description: Dietary

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet B
Description: Dietary

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet C
Description: Dietary

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet C
Description: Dietary

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet C
Description: Dietary
Study: NCT00613821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 5 milliliter intrauterine infusion of 4% lidocaine, infusion will be placed slowly over 3 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Standard paracervical block (8 milliliter 1% lidocaine at 4 and 8 o'clock at the cervical-vaginal reflection) will be placed.
Study: NCT02403011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soft tissue mobilization
Description: soft tissue mobilization technique has three phases. First phase 'the passive mobilization phase' is applied by gentle but tight gripping of the SKM muscle two or three fingers below the muscle origo and the muscle is mobilized rhythmically in the antero-posterior direction. Secondly, after gently continue to hold the muscle the baby was encouraged to do active repetitive cervical rotation to the affected side by means of catching the babies attention with colored and sonorous toys. Third phase was mobilization with stretching. Caregiver holds the baby on his/ her affected side while the therapist gently grips and withholds the muscle. Therapist mobilizes the muscle in the antero-posterior direction and stretch the muscle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home program controlled once six weeks
Description: Home program which consisted of positioning the neck and head, handling strategies, stretching exercises, strengthening exercises according to babies neurodevelopmental level and environmental adaptations
Study: NCT00048035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Differing doses and frequencies of iv administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Differing doses and frequencies of iv administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Differing doses and frequencies of iv administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Differing doses and frequencies of iv administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Differing doses and frequencies of iv administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Differing doses and frequencies of iv administration
Study: NCT03052881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot assisted surgery
Description: The PRECEYES Surgical System is a robotically assistive device developed by PRECEYES Medical Robotics, a Dutch-based research group at the Technische Universiteit Eindhoven. It has been designed to enhance surgical precision, specifically for vitreoretinal eye surgery. The device provides accuracy beyond human capabilities of \<10μm in all directions (x, y, z planes). The surgeon is always in control of the instrument by manipulating the motion controller.
Study: NCT04188873

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Counseling
Description: 2 brief phone or video counseling sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Counseling
Description: 2 brief phone or video counseling sessions
Study: NCT04089254

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient Psychiatry
Description: Inpatient hospitalization to treat and stabilize suicidal thoughts and behavior.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient Crisis Intervention Clinic
Description: Outpatient psychiatric clinic that provides crisis intervention to treat and stabilize suicidal thoughts and behavior.
Study: NCT02292459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol 3350 Powder for Solution (PEG 3350)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol 4000 Powder for Solution (PEG 4000)
Study: NCT01099358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 - Fluorouracil
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 - Fluorouracil
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 - Fluorouracil
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 - Fluorouracil
Description: Administered Intravenously
Study: NCT03414853

Intervention type: DIAGNOSTIC_TEST
Intervention: Free text prediction algorithm for appendicitis
Description: A free-text prediction software that predicts the probability of acute appendicitis
Study: NCT03059732

Intervention type: OTHER
Intervention: Treatment
Description: Observe the treatments of gastric cancer in each group

Intervention type: OTHER
Intervention: Treatment
Description: Observe the treatments of gastric cancer in each group
Study: NCT01407809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venous Sinus Stenting
Description: Venous sinus stenting consists of placing a stent into the narrowed veins of the brain.
Study: NCT02037815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20% mannitol solution, 125 ml, IV infusion in 15 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.1% sodium chloride solution, 125 ml, IV infusion in 15 min
Study: NCT01716663

Intervention type: DEVICE
Intervention: Catheter Ablation
Description: NAVISTAR® THERMOCOOL® SF Catheter with the CARTO® 3 System and the SOUNDSTAR® Ultrasound Catheter (with the CARTOSOUND® Software Module)
Study: NCT01936363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib once daily
Description: Pimasertib administered as oral capsule at a dose of 60 milligram (mg) once daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib placebo
Description: Placebo matching Pimasertib administered once daily in evening until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245409 placebo
Description: Placebo matching SAR245409 administered once daily in morning until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245409
Description: SAR245409 administered as oral capsule at a dose of 70 milligram (mg) once daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib twice daily
Description: Pimasertib administered as oral capsule at a dose of 60 milligram (mg) twice daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
Study: NCT02090504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate (SMO)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxazepam
Study: NCT04685252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (BL) NCC3001
Description: Probiotic strain (BL) NCC3001 packed in stickpack, to be consumed daily.
Study: NCT04685252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (BL) NCC3001
Description: Probiotic strain (BL) NCC3001 packed in stickpack, to be consumed daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo containing maltodextrin packed in stickpack, to be consumed daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo containing maltodextrin packed in stickpack, to be consumed daily.
Study: NCT03158961

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral endoscopic thyroidectomy vestibular approach
Description: TOVETA is a new approach in surgery of thyroidectomy no longer open on the neck
Study: NCT02671851

Intervention type: DRUG
Intervention: Thoracic paravertebral blocks (TPVBs)
Description: Patients received bilateral single injection ultrasound-guided TPVBs with 20mL bupivacaine 0.375% at the level of T3-T4 as an adjunct to GA, intraoperative fentanyl and postoperative tramadol, metamizole sodium and paracetamol were used.

Intervention type: DRUG
Intervention: IV metamizole sodium, paracetamol
Description: Patients received only standardized GA, intraoperative fentanyl and postoperative tramadol, metamizole sodium and paracetamol were used.
Study: NCT04245592

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil
Description: Before beginning the 3-week dietary trial, participants will conduct a 2-week washout period during which they consumed ROO (50 ml daily for 2 weeks) because they are part of a population that consumes olive oil regularly. After thar, patients of this groups will consume 50 ml/day of organic EVOO for 3 weeks. Biochemical markers and clinical parameters in each participant will be determine before and after the 3-week treatment period.
Study: NCT00452023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN-alpha2a
Description: Starting dose 90 microgram (mcg) injection under the skin once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN-alpha2a
Description: Starting dose 90 microgram (mcg) injection under the skin once a week
Study: NCT04245592

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Refined Olive Oil
Description: Before beginning the 3-week dietary trial, participants will conduct a 2-week washout period during which they consumed ROO (50 ml daily for 2 weeks) because they are part of a population that consumes olive oil regularly. After thar, patients of this groups will consume 50 ml/day of ROO for 3 weeks. Biochemical markers and clinical parameters in each participant will be determine before and after the 3-week treatment period.
Study: NCT01224275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group based care
Description: Midwives is randomized and allocated to group based antenatal care. The midwives have a manual for the model of care.
Study: NCT04033146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Exoskeleton Assistance
Description: The investigators will use ankle-exoskeletons to modulate the amount of mechanical power generated by the user's ankle joint. That is, participants will walk in a robotic device that either (a) adds a spring or (b) a motor in parallel with their calf muscles to help them generate a stronger propulsive push-off that could reduce the effort of walking.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Exoskeleton Assistance
Description: The investigators will use ankle-exoskeletons to modulate the amount of mechanical power generated by the user's ankle joint. That is, participants will walk in a robotic device that either (a) adds a spring or (b) a motor in parallel with their calf muscles to help them generate a stronger propulsive push-off that could reduce the effort of walking.
Study: NCT02351401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education using ultrasonography as feedback tool
Description: Education using ultrasonography as feedback tool
Study: NCT01252771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PKM Algorithm
Description: The subject's serum calcium and phosphorus values will be input into PKM in order to determine the required PhosLo prescription. The prescription is determined as the number of gelcaps per day that must be taken by the subject.~If PKM determines the number of PhosLo gelcaps per day to be greater than or equal to the subject's current prescription, then PKM will calculate the current Ca++ and phosphate balance. Furthermore, the PKM algorithm will determine the additional number of PhosLo gelcaps needed to achieve neutral phosphate (P) balance with serum P reduced to 5.5 mg/dL.~The PKM algorithm also calculates the total P intake between dialyses and along with ePCR also calculates a Phosphorus/Protein Ratio (PPR). This ratio ranges from 8 to 14 in dialysis patients following a renal diet.
Study: NCT00141518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADD-Legacy® 1400 ambulatory infusion pump

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADD-Legacy® 1400 ambulatory infusion pump

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADD-Legacy® 1400 ambulatory infusion pump

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous endoscopic gastrostomy tube (PEG tube)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous endoscopic gastrostomy tube (PEG tube)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous endoscopic gastrostomy tube (PEG tube)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: jejunal extension tube (J-tube)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: jejunal extension tube (J-tube)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: jejunal extension tube (J-tube)
Study: NCT02106780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-labeled ASP1707
Description: oral
Study: NCT00959465

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H1N1 pandemic influenza vaccine (whole virion, Vero Cell-derived, inactivated)
Description: Two injections at a 21-day interval (Days 1 and 22)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H1N1 pandemic influenza vaccine (whole virion, Vero Cell-derived, inactivated)
Description: Two injections at a 21-day interval (Days 1 and 22)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H1N1 pandemic influenza vaccine (whole virion, Vero Cell-derived, inactivated)
Description: Two injections at a 21-day interval (Days 1 and 22)
Study: NCT02821429

Intervention type: OTHER
Intervention: Combined Thoracic Echography Record
Description: This examination will be done to do the longitudinal follow-up of the patient
Study: NCT01142934

Intervention type: DEVICE
Group type: OTHER
Intervention: Transparent adhesive dressing with an integrated gel pad containing 2% w/w chlorhexidine gluconate (CHG) (TegaDerm CHG)
Description: The intervention is represented by the combination of the TegaDerm transparent adhesive dressing with an integrated gel pad containing 2% w/w chlorhexidine gluconate (CHG), an antiseptic agent with broad spectrum antimicrobial and antifungal activity.
Study: NCT01043978

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Use of baby bottle nipple
Description: Participants will be assigned to either a novel nipple or a conventional nipple to use when feeding their infants with the bottle

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of baby bottle nipple
Description: Participants will be assigned to either a novel nipple or a conventional nipple to use when feeding their infants with the bottle
Study: NCT03967288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine Injection [Clorotekal]
Description: 1% chloroprocaine Hydrochloride Injection (50 mg/5 mL) for intrathecal use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride 0.75% Injection Solution
Description: 0.75% bupivacaine Hydrochloride injection in 8.25% dextrose for intrathecal use
Study: NCT05022277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low tech health SMS messages
Description: Weekly health-related SMS messages are provided to adolescents.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low tech health Phone + SMS messages
Description: Weekly health-related phone calls plus SMS messages are provided to adolescents.
Study: NCT00764569

Intervention type: DEVICE
Intervention: Fluorescence/Elastic Scattering Spectroscopy
Description: Fluorescence/Elastic Scattering Spectroscopy Oral tissue measurement
Study: NCT04616716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMTN
Description: Single dose of FMTN after high-fat meal,low-fat meal and fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMTN
Description: Single dose of FMTN after high-fat meal,low-fat meal and fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMTN
Description: Single dose of FMTN after high-fat meal,low-fat meal and fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMTN
Description: Single dose of FMTN after high-fat meal,low-fat meal and fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMTN
Description: Single dose of FMTN after high-fat meal,low-fat meal and fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMTN
Description: Single dose of FMTN after high-fat meal,low-fat meal and fast
Study: NCT00452023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN-alpha2a
Description: Starting dose 90 microgram (mcg) injection under the skin once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN-alpha2a
Description: Starting dose 90 microgram (mcg) injection under the skin once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN-alpha2a
Description: Starting dose 90 microgram (mcg) injection under the skin once a week